research use only

Amantadine HCl Dopamine Receptor agonist

Name: Amantadine HCl
Brand: Selleck Chemicals
SKU: S2451
Availability: InStock
Rating: 5 (4 reviews)

Cat.No.S2451

Amantadine HCl has antiviral and anti-parkinsonian activities and is used to treat or prevent respiratory infections caused by certain viruses. It is also widely used in the treatment of Parkinson's disease.

Chemical Structure

Molecular Weight: 187.7

Jump to

Quality Control

Batch: Purity: >97%

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS/MSDS

Cited in Nature Medicine for its top-tier quality
COA
NMR
Datasheet
SDS/MSDS

Related Targets	Adrenergic Receptor AChR 5-HT Receptor COX Calcium Channel Histamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR
Other Dopamine Receptor Inhibitors	MPTP Hydrochloride Trifluoperazine Trifluoperazine 2HCl Penfluridol Rotundine Domperidone Sulpiride Azaperone ONC206 SCH-23390 hydrochloride

Solubility

In vitro
Batch:

DMSO : 38 mg/mL (202.45 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 38 mg/mL

Ethanol : 38 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Clear solution	saline Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	120.000mg/ml (639.32mM)	Taking the 1 mL working solution as an example, add 120 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	187.7	Formula	C₁₀H₁₇N.HCl	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	665-66-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	1-adamantanamine HCl			SMILES	C1C2CC3CC1CC(C2)(C3)N.Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	Dopamine receptor

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-03-04)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04302870	RECRUITING	Motor Neuron Disease, Amyotrophic Lateral Sclerosis	University of Edinburgh	2020-02-27	PHASE2; PHASE3
NCT05140148	RECRUITING	Stroke, Ischemic; Stroke Hemorrhagic	University of Pennsylvania	2022-02-01	PHASE2
NCT07421427	RECRUITING	Amantadine; Duloxetine; Pregabalin; Mastectomy; Pain Syndrome	Cairo University	2026-02-21
NCT06055244	COMPLETED	Long COVID; Post-COVID19 Condition; Post-Acute COVID19 Syndrome	Ohio State University	2023-12-07	PHASE2
NCT06234462	WITHDRAWN	Long COVID; Post-Acute COVID-19 Syndrome	University of Texas Southwestern Medical Center	2025-06	PHASE2
NCT06253923	ACTIVE_NOT_RECRUITING	Traumatic Brain Injury	SHINKEI Therapeutics, Inc	2024-06-01	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):